Cargando…
The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test
BACKGROUND: Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg, causes major complications. HVPG is not always available, so a non-invasive tool to diagnose CSPH would be useful. VWF-Ag can be used to diagnose. Using the VITRO score (the VW...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760704/ https://www.ncbi.nlm.nih.gov/pubmed/26895398 http://dx.doi.org/10.1371/journal.pone.0149230 |
_version_ | 1782416891454685184 |
---|---|
author | Hametner, Stephanie Ferlitsch, Arnulf Ferlitsch, Monika Etschmaier, Alexandra Schöfl, Rainer Ziachehabi, Alexander Maieron, Andreas |
author_facet | Hametner, Stephanie Ferlitsch, Arnulf Ferlitsch, Monika Etschmaier, Alexandra Schöfl, Rainer Ziachehabi, Alexander Maieron, Andreas |
author_sort | Hametner, Stephanie |
collection | PubMed |
description | BACKGROUND: Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg, causes major complications. HVPG is not always available, so a non-invasive tool to diagnose CSPH would be useful. VWF-Ag can be used to diagnose. Using the VITRO score (the VWF-Ag/platelet ratio) instead of VWF-Ag itself improves the diagnostic accuracy of detecting cirrhosis/ fibrosis in HCV patients. AIM: This study tested the diagnostic accuracy of VITRO score detecting CSPH compared to HVPG measurement. METHODS: All patients underwent HVPG testing and were categorised as CSPH or no CSPH. The following patient data were determined: CPS, D’Amico stage, VITRO score, APRI and transient elastography (TE). RESULTS: The analysis included 236 patients; 170 (72%) were male, and the median age was 57.9 (35.2–76.3; 95% CI). Disease aetiology included ALD (39.4%), HCV (23.4%), NASH (12.3%), other (8.1%) and unknown (11.9%). The CPS showed 140 patients (59.3%) with CPS A; 56 (23.7%) with CPS B; and 18 (7.6%) with CPS C. 136 patients (57.6%) had compensated and 100 (42.4%) had decompensated cirrhosis; 83.9% had HVPG ≥10 mmHg. The VWF-Ag and the VITRO score increased significantly with worsening HVPG categories (P<0.0001). ROC analysis was performed for the detection of CSPH and showed AUC values of 0.92 for TE, 0.86 for VITRO score, 0.79 for VWF-Ag, 0.68 for ELF and 0.62 for APRI. CONCLUSION: The VITRO score is an easy way to diagnose CSPH independently of CPS in routine clinical work and may improve the management of patients with cirrhosis. |
format | Online Article Text |
id | pubmed-4760704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-47607042016-03-07 The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test Hametner, Stephanie Ferlitsch, Arnulf Ferlitsch, Monika Etschmaier, Alexandra Schöfl, Rainer Ziachehabi, Alexander Maieron, Andreas PLoS One Research Article BACKGROUND: Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg, causes major complications. HVPG is not always available, so a non-invasive tool to diagnose CSPH would be useful. VWF-Ag can be used to diagnose. Using the VITRO score (the VWF-Ag/platelet ratio) instead of VWF-Ag itself improves the diagnostic accuracy of detecting cirrhosis/ fibrosis in HCV patients. AIM: This study tested the diagnostic accuracy of VITRO score detecting CSPH compared to HVPG measurement. METHODS: All patients underwent HVPG testing and were categorised as CSPH or no CSPH. The following patient data were determined: CPS, D’Amico stage, VITRO score, APRI and transient elastography (TE). RESULTS: The analysis included 236 patients; 170 (72%) were male, and the median age was 57.9 (35.2–76.3; 95% CI). Disease aetiology included ALD (39.4%), HCV (23.4%), NASH (12.3%), other (8.1%) and unknown (11.9%). The CPS showed 140 patients (59.3%) with CPS A; 56 (23.7%) with CPS B; and 18 (7.6%) with CPS C. 136 patients (57.6%) had compensated and 100 (42.4%) had decompensated cirrhosis; 83.9% had HVPG ≥10 mmHg. The VWF-Ag and the VITRO score increased significantly with worsening HVPG categories (P<0.0001). ROC analysis was performed for the detection of CSPH and showed AUC values of 0.92 for TE, 0.86 for VITRO score, 0.79 for VWF-Ag, 0.68 for ELF and 0.62 for APRI. CONCLUSION: The VITRO score is an easy way to diagnose CSPH independently of CPS in routine clinical work and may improve the management of patients with cirrhosis. Public Library of Science 2016-02-19 /pmc/articles/PMC4760704/ /pubmed/26895398 http://dx.doi.org/10.1371/journal.pone.0149230 Text en © 2016 Hametner et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hametner, Stephanie Ferlitsch, Arnulf Ferlitsch, Monika Etschmaier, Alexandra Schöfl, Rainer Ziachehabi, Alexander Maieron, Andreas The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title | The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title_full | The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title_fullStr | The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title_full_unstemmed | The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title_short | The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test |
title_sort | vitro score (von willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including elf test |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760704/ https://www.ncbi.nlm.nih.gov/pubmed/26895398 http://dx.doi.org/10.1371/journal.pone.0149230 |
work_keys_str_mv | AT hametnerstephanie thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ferlitscharnulf thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ferlitschmonika thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT etschmaieralexandra thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT schoflrainer thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ziachehabialexander thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT maieronandreas thevitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT hametnerstephanie vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ferlitscharnulf vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ferlitschmonika vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT etschmaieralexandra vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT schoflrainer vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT ziachehabialexander vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest AT maieronandreas vitroscorevonwillebrandfactorantigenthrombocyteratioasanewmarkerforclinicallysignificantportalhypertensionincomparisontoothernoninvasiveparametersoffibrosisincludingelftest |